E.W. Muller

1.9k total citations
19 papers, 547 citations indexed

About

E.W. Muller is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, E.W. Muller has authored 19 papers receiving a total of 547 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 5 papers in Pathology and Forensic Medicine and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in E.W. Muller's work include Colorectal Cancer Treatments and Studies (6 papers), Genetic factors in colorectal cancer (5 papers) and Cancer Treatment and Pharmacology (5 papers). E.W. Muller is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Genetic factors in colorectal cancer (5 papers) and Cancer Treatment and Pharmacology (5 papers). E.W. Muller collaborates with scholars based in Netherlands, United States and Denmark. E.W. Muller's co-authors include Rutger Meinsma, Janet Haasjes, Hans R. Waterham, Frank Baas, André B. P. Kuilenburg, Lida Zoetekouw, Albert H. Gennip, Dick J. Richel, Cornelis J.A. Punt and Miriam Koopman and has published in prestigious journals such as Journal of Clinical Oncology, Kidney International and Annals of Oncology.

In The Last Decade

E.W. Muller

19 papers receiving 531 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E.W. Muller Netherlands 12 397 163 133 53 48 19 547
M Schneider France 12 446 1.1× 196 1.2× 137 1.0× 124 2.3× 31 0.6× 54 759
Helgi H. Helgason Netherlands 9 278 0.7× 113 0.7× 149 1.1× 114 2.2× 91 1.9× 21 449
Nathalie Letarte Canada 10 221 0.6× 137 0.8× 141 1.1× 33 0.6× 33 0.7× 26 477
Arzu Yaren Türkiye 14 283 0.7× 137 0.8× 138 1.0× 45 0.8× 82 1.7× 51 550
Fernando Gaion Italy 8 411 1.0× 199 1.2× 143 1.1× 33 0.6× 48 1.0× 11 541
R. Jackson Forcier United States 11 427 1.1× 207 1.3× 133 1.0× 36 0.7× 54 1.1× 18 785
J Lokich United States 9 470 1.2× 102 0.6× 154 1.2× 62 1.2× 38 0.8× 15 574
Laurence Venat‐Bouvet France 14 366 0.9× 96 0.6× 138 1.0× 45 0.8× 181 3.8× 40 647
Jan Ouwerkerk Netherlands 11 250 0.6× 153 0.9× 109 0.8× 34 0.6× 43 0.9× 17 506
J. Hartlapp Germany 13 150 0.4× 95 0.6× 117 0.9× 58 1.1× 35 0.7× 48 483

Countries citing papers authored by E.W. Muller

Since Specialization
Citations

This map shows the geographic impact of E.W. Muller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E.W. Muller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E.W. Muller more than expected).

Fields of papers citing papers by E.W. Muller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E.W. Muller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E.W. Muller. The network helps show where E.W. Muller may publish in the future.

Co-authorship network of co-authors of E.W. Muller

This figure shows the co-authorship network connecting the top 25 collaborators of E.W. Muller. A scholar is included among the top collaborators of E.W. Muller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E.W. Muller. E.W. Muller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Poort, Hanneke, A.N.M. Wymenga, Jan Willem de Groot, et al.. (2020). Informal caregiver well-being during and after patients’ treatment with adjuvant chemotherapy for colon cancer: a prospective, exploratory study. Supportive Care in Cancer. 29(5). 2481–2491. 15 indexed citations
2.
Kwakman, Johannes J.M., Lieke H. J. Simkens, Johan M. van Rooijen, et al.. (2017). Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. Annals of Oncology. 28(6). 1288–1293. 47 indexed citations
3.
Kwakman, Johannes J.M., Lieke H. J. Simkens, Johan M. van Rooijen, et al.. (2017). Randomised phase 3 study of S-1 versus capecitabine, with bevacizumab optional in both arms, in the first-line treatment of metastatic colorectal cancer (mCRC), the SALTO study of the Dutch Colorectal Cancer Group. European Journal of Cancer. 72. S5–S5. 1 indexed citations
4.
Punt, Cornelis J.A., Lieke H. J. Simkens, Johan van Rooijen, et al.. (2016). Randomized phase 3 study of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (mCRC): The SALTO study of the Dutch Colorectal Cancer Group.. Journal of Clinical Oncology. 34(15_suppl). 3640–3640. 2 indexed citations
5.
Muller, E.W., et al.. (2014). [Acute coronary syndrome after chemotherapy].. PubMed. 158. A6940–A6940. 1 indexed citations
6.
Aarts, Maureen J.B., Frank Peters, Caroline M.P.W. Mandigers, et al.. (2013). Primary Granulocyte Colony-Stimulating Factor Prophylaxis During the First Two Cycles Only or Throughout All Chemotherapy Cycles in Patients With Breast Cancer at Risk for Febrile Neutropenia. Journal of Clinical Oncology. 31(34). 4290–4296. 38 indexed citations
7.
Simkens, Lieke H. J., Miriam Koopman, Linda Mol, et al.. (2011). Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy. European Journal of Cancer. 47(17). 2560–2567. 74 indexed citations
8.
9.
10.
Kuip, Evelien & E.W. Muller. (2009). Fatal pneumonitis after treatment with docetaxel and trastuzumab.. Data Archiving and Networked Services (DANS). 67(6). 237–9. 18 indexed citations
11.
Koopman, Miriam, E.W. Muller, & Cornelis J.A. Punt. (2008). Reversible Posterior Leukoencephalopathy Syndrome Caused by Bevacizumab: Report of a Case. Diseases of the Colon & Rectum. 51(9). 1425–1426. 18 indexed citations
12.
Muller, E.W., et al.. (2005). [Eating disorders in the physician's office--the first interview may be decisive].. PubMed. 147(7). 44–5, 47. 1 indexed citations
13.
Punt, Cornelis J.A., H.J. Keizer, J. Douma, et al.. (2002). Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. Annals of Oncology. 13(1). 81–86. 21 indexed citations
14.
Kuilenburg, André B. P., E.W. Muller, Janet Haasjes, et al.. (2001). Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.. PubMed. 7(5). 1149–53. 202 indexed citations
15.
Punt, Cornelis J. A., H.J. Keizer, J. Douma, et al.. (1999). Phase III trial of 5-fluorouracil (5FU) and leucovorin (LV) with or without trimetrexate (TMTX) as first line treatment in advanced colorectal cancer (ACC). European Journal of Cancer. 35. S68–S68. 1 indexed citations
16.
Muller, E.W., J. Th. M. de Wolf, & Edo Vellenga. (1993). SUCCESSFUL IMMUNOSUPPRESSIVE TREATMENT AFTER FAILURE OF ERYTHROPOIETIN THERAPY IN TWO SUBJECTS WITH REFRACTORY ANAEMIA. British Journal of Haematology. 83(1). 171–172. 5 indexed citations
17.
Muller, E.W., et al.. (1992). Explantation of mesangial cell 'hillocks': a method for obtaining human mesangial cells in culture.. PubMed. 73(1). 9–20. 10 indexed citations
18.
Woude, Fokko J. van der, et al.. (1989). Lymphohaemopoietic antigens of cultured human glomerular epithelial cells.. PubMed. 70(1). 73–82. 12 indexed citations
19.
Grond, Joris, E.W. Muller, Harry van Goor, Jan J. Weening, & Job D. Elema. (1988). Differences in puromycin aminonucleoside nephrosis in two rat strains. Kidney International. 33(2). 524–529. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M Schneider Breakdown of academic impact, for papers by Helgi H. Helgason Breakdown of academic impact, for papers by Nathalie Letarte Breakdown of academic impact, for papers by Arzu Yaren Breakdown of academic impact, for papers by Fernando Gaion Breakdown of academic impact, for papers by R. Jackson Forcier Breakdown of academic impact, for papers by J Lokich Breakdown of academic impact, for papers by Laurence Venat‐Bouvet Breakdown of academic impact, for papers by Jan Ouwerkerk Breakdown of academic impact, for papers by J. Hartlapp
Rankless by CCL
2026